Amanda Menezes Mayer

Ms. Amanda Menezes Mayer

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
PFPatrícia Ferrareze
Patrícia Ferrareze
VFVinícius Bonetti Franceschi
Vinícius Bonetti Franceschi
Amanda Menezes MayerAmanda Menezes Mayer
Amanda Menezes Mayer
GCGabriel Caldana
Gabriel Caldana
RZRicardo Ariel Zimerman
Ricardo Ariel Zimerman
CTClaudia Elizabeth Thompson
Claudia Elizabeth Thompson
The COVID-19 pandemic caused by SARS-CoV-2 has affected millions of people since its beginning in 2019. The propagation of new lineages and the discovery of key mechanisms adopted by the virus to overlap the immune system are central topics for the entire public health policies, research and disease management. Since the second semester of 2020, the mutation E484K has been progressively found in the Brazilian territory, composing different lineages over time. It brought multiple concerns related to the risk of reinfection and the effectiveness of new preventive and treatment strategies due to the possibility of escaping from neutralizing antibodies. To better characterize the current scenario we performed genomic and phylogenetic analyses of the E484K mutated genomes sequenced from Brazilian samples in 2020. From October, 2020, more than 40% of the sequenced genomes present the E484K mutation, which was identified in three different lineages (P1, P2 and B.1.1.33) in four Brazilian regions. We also evaluated the presence of E484K associated mutations and identified selective pressures acting on the spike protein, leading us to some insights about adaptive and purifying selection driving the virus evolution.

10 January 2025 in Hematology Reports
Verified
Journal Article
Open access
PDF file
JDJessica Dorneles
Jessica Dorneles
Amanda Menezes MayerAmanda Menezes Mayer
Amanda Menezes Mayer
José Artur Bogo ChiesJosé Artur Bogo Chies
José Artur Bogo Chies
A quarter of a century ago, sickle cell disease (SCD) was mainly viewed as a typical genetic disease inherited as a classical Mendelian trait. Therefore, the main focus concerning SCD was on diagnosis, meaning, genotyping, and identification of homozygous and heterozygous individuals carrying the relevant HbS mutant allele. Nowadays, it is well established that sickle cell disease is indeed the result of homozygosis for the HbS variant, although this single feature is not capable of explaining the highly diverse clinical presentation of SCD. In fact, an important feature of SCD is the chronic inflammation that accompanies the sickling of erythrocytes. In this manuscript, we will revisit the early evidence of inflammation in SCD and review what was uncovered during the last 25 years. Here, we describe Sickle cell anemia as a major participant in the history of science. In fact, SCD was the first genetic disease where the causal mutation was identified and is also the first disease for which treatment through genome editing was approved, making this disease a landmark in the road of molecular biology.

22 October 2020 in medRxiv
Verified
Preprint
Open access
PDF file
VFVinícius Bonetti Franceschi
Vinícius Bonetti Franceschi
ASAndressa Schneiders Santos
Andressa Schneiders Santos
AGAndressa Barreto Glaeser
Andressa Barreto Glaeser
JPJanini Cristina Paiz
Janini Cristina Paiz
GCGabriel Caldana
Gabriel Caldana
CTClaudia Elizabeth Thompson
Claudia Elizabeth Thompson
Population-based prevalence surveys of COVID-19 contribute to establish the burden and epidemiology of infection, the role of asymptomatic and mild infections in transmission, and allow more precise decisions about reopen policies. We performed a systematic review to evaluate qualitative aspects of these studies, their reliability, and biases. The available data described 37 surveys from 19 countries, mostly from Europe and America and using antibody testing. They reached highly heterogeneous sample sizes and prevalence estimates. Disproportional prevalence was observed in minority communities. Important risk of bias was detected in four domains: sample size, data analysis with sufficient coverage, measurements in standard way, and response rate. The correspondence analysis showed few consistent patterns for high risk of bias. Intermediate risk of bias was related to American and European studies, blood samples and prevalence >1%. Low risk of bias was related to Asian studies, RT-PCR tests and prevalence <1%. One sentence summary Population-based prevalence surveys of COVID-19 until September 2020 were mostly conducted in Europe and Americas, used antibody testing, and had important risks of bias.